GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Procter & Gamble Health Ltd (NSE:PGHL) » Definitions » Debt-to-EBITDA

Procter & Gamble Health (NSE:PGHL) Debt-to-EBITDA : 0.02 (As of Dec. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Procter & Gamble Health Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Procter & Gamble Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹28 Mil. Procter & Gamble Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹55 Mil. Procter & Gamble Health's annualized EBITDA for the quarter that ended in Dec. 2024 was ₹5,096 Mil. Procter & Gamble Health's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was 0.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Procter & Gamble Health's Debt-to-EBITDA or its related term are showing as below:

NSE:PGHL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01   Med: 0.03   Max: 0.04
Current: 0.02

During the past 13 years, the highest Debt-to-EBITDA Ratio of Procter & Gamble Health was 0.04. The lowest was 0.01. And the median was 0.03.

NSE:PGHL's Debt-to-EBITDA is ranked better than
96.6% of 676 companies
in the Drug Manufacturers industry
Industry Median: 1.66 vs NSE:PGHL: 0.02

Procter & Gamble Health Debt-to-EBITDA Historical Data

The historical data trend for Procter & Gamble Health's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Procter & Gamble Health Debt-to-EBITDA Chart

Procter & Gamble Health Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Jun21 Jun22 Jun23 Jun24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.03 0.01 0.04 0.03

Procter & Gamble Health Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 - 0.08 - 0.02

Competitive Comparison of Procter & Gamble Health's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Procter & Gamble Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Procter & Gamble Health's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Procter & Gamble Health's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Procter & Gamble Health's Debt-to-EBITDA falls into.


;
;

Procter & Gamble Health Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Procter & Gamble Health's Debt-to-EBITDA for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(26.8 + 68.8) / 3014.4
=0.03

Procter & Gamble Health's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(27.6 + 55.2) / 5095.6
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.


Procter & Gamble Health  (NSE:PGHL) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Procter & Gamble Health Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Procter & Gamble Health's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Procter & Gamble Health Business Description

Traded in Other Exchanges
Address
Cardinal Gracias Road, Ground Floor And First Floor, P&G Plaza, Chakala, Andheri East, Mumbai, MH, IND, 400099
Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company's distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.